We are live on ! Find out more
CEROW

CERo Therapeutics Warrants
CEROW

Delisted

CEROW was delisted on the 30th of October, 2025.

Back to rankings

43 hedge funds and large institutions have $2.19M invested in CERo Therapeutics Warrants in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $2.03M → $2.19M (+$155K)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

7% less funds holding

Funds holding: 46 → 43 (-3)

70% less call options, than puts

Call options by funds: $7K | Put options by funds: $23K

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
43
Holders Change
-3
Holders Change %
-6.52%
% of All Funds
0.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
5
Closed
4
Calls
$7K
Puts
$23K
Net Calls
-$16K
Net Calls Change
-$20K

Top Buyers

Rank Fund Capital Flow
1
SFM
Spartan Fund Management
Canada
+$3.4K
2
YCM
Yakira Capital Management
Connecticut
+$2.17K
3
RCM
Robinson Capital Management
Michigan
+$159
4
CS
Clear Street
New York
+$88
5
HF
HRT Financial
New York
+$15

Top Sellers

Rank Fund Capital Flow
1
SCM
Shaolin Capital Management
Florida
-$16.3K
2
SRCM
Sage Rock Capital Management
New York
-$3.69K
3
DCM
Difesa Capital Management
New York
-$2.51K
4
SG
StoneX Group
New York
-$911
5
CH
CVI Holdings
Delaware
-$778
Name Holding Trade Value Shares
Change 		Change in
Stake
MP
1
Mangrove Partners
Connecticut
$1.78M – – –
PC
2
Periscope Capital
Ontario, Canada
$61.9K – – –
SCM
3
Segantii Capital Management
Hong Kong
$54.5K – – –
HCM
4
Highbridge Capital Management
New York
$43.6K – – –
MI
5
MMCAP International
Cayman Islands
$22.9K – – –
CF
6
Cantor Fitzgerald
New York
$22.2K – – –
SCM
7
Saba Capital Management
New York
$19.4K – – –
PAMP
8
Polar Asset Management Partners
Ontario, Canada
$18.3K – – –
LA
9
Linden Advisors
New York
$16.4K – – –
AA
10
AQR Arbitrage
Connecticut
$15.1K -$12 -286 -0.1%
ACM
11
Atalaya Capital Management
New York
$13.5K – – –
CCA
12
Castle Creek Arbitrage
Colorado
$12.2K – – –
CCM
13
Context Capital Management
California
$12K – – –
QGA
14
Q Global Advisors
Texas
$10K – – –
RCM
15
Radcliffe Capital Management
Pennsylvania
$9.82K – – –
NAM
16
Nexpoint Asset Management
Texas
$6.64K – – –
Parallax Volatility Advisers
17
Parallax Volatility Advisers
California
$6.54K -$607 -13,996 -12%
CS
18
Clear Street
New York
$5.48K +$88 +2,031 +2%
WAM
19
Wolverine Asset Management
Illinois
$5.37K – – –
PMAM
20
Picton Mahoney Asset Management
Ontario, Canada
$5K – – –
WCMNY
21
Westchester Capital Management (New York)
New York
$4.58K – – –
CAC
22
Cowen and Company
New York
$3.54K – – –
KL
23
KIM LLC
Kansas
$3.27K – – –
YCM
24
Yakira Capital Management
Connecticut
$3.27K +$2.17K +49,999 New
SFM
25
Spartan Fund Management
Canada
$3.27K +$3.4K +78,423 +314%
1
2

CEROW Hedge Fund Activity: Q2 2023 in Review

43 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics Warrants (CEROW) for Q2 2023, worth a combined $2.19M — up 7.6% from $2.03M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CEROW and 1 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 5 added.

The largest buyer was Spartan Fund Management, adding an estimated $3.4K. The largest seller was Shaolin Capital Management, exiting entirely with an estimated $16.3K sold.

  • 43 institutional investors held CERo Therapeutics Warrants (CEROW) as of Q2 2023, down from 46 in Q1 2023.
  • Funds reported $2.19M of CERo Therapeutics Warrants stock for Q2 2023, up 7.6% quarter-over-quarter.
  • 1 fund opened new CERo Therapeutics Warrants positions in Q2 2023 and 4 closed out, a net change of -3 holders.
  • The largest CERo Therapeutics Warrants buyer in Q2 2023 was Spartan Fund Management, an estimated $3.4K added.
  • The largest CERo Therapeutics Warrants seller in Q2 2023 was Shaolin Capital Management, an estimated $16.3K sold.

Based on aggregated 13F filings for Q2 2023.